大森控股(01580.HK)擬“5股獲發3股”發售股份 每手買賣單位更改為30000股
格隆匯9月1日丨大森控股(01580.HK)公吿,於2021年9月1日,董事會議決進一步調整經修訂公開發售的條款,並將按合資格股東於記錄日期每持有5股股份獲發3股發售股份的基準按每股發售股份0.04港元的發售價實施。假設公司已發行股本於本公吿日期至記錄日期並無變動,5.85億股發售股份相當於已發行股本的60.0%及經發行發售股份擴大後已發行股本的約37.5%。
由於股份按低於每手買賣單位2,000港元進行買賣,董事會建議於完成經修改公開發售後將於聯交所買賣的每手買賣單位由5,000股股份更改為30,000股股份。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.